Ad
related to: clopidogrel generic picturesGoodRx was honored as dot.LA’s Startup of the Year for 2020. - dot.LA
Search results
Results from the WOW.Com Content Network
Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009. [45] It was the second-top-selling drug in the world in 2007 [46] and was still growing by over 20% in 2007. US sales were US$3.8 billion in 2008. [47] Before the expiry of its patent, clopidogrel was the second best-selling drug in the world.
Clopidogrel has a common drug interaction with CYP2C19 inhibitors, particularly omeprazole and esomeprazole which are indicated for treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD). As the activation of clopidogrel requires an enzyme called CYP2C19, its inhibitors should be avoided. [38]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
English: Skeletal formula of clopidogrel (original brand name Plavix ...
Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine (trade name Ticlid) and clopidogrel (trade name Plavix). These agents reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y 12 receptors. Prasugrel inhibits platelet aggregation more rapidly, more consistently, and to a ...
In some countries, such as Brazil (photo) and France, more than 20% of all drug sales in units are generic. A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire.
[55] [57] An interaction between PPIs and the metabolism of the platelet inhibitor clopidogrel is known and this drug is also often used in people with cardiac disease. [ 58 ] [ 59 ] [ 22 ] There are associations with an increased risk of stroke, but this appears to be more likely to occur in people who already have an elevated risk.
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.